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compression. Moreover, the complication rate appears similar for
interventional procedures for the market-leading products, Angio-
Seal and Perclose, with a higher complication rate seen with the
VasoSeal device (1).
As with other interventional technologies, an evolution has
occurred in closure device technology that outpaces the published
data. In our own portfolio of Perclose suture closure products, key
improvements have been seen with each generation of product.
The Closer product was introduced in 1999 and saw a fundamental
change with needles that captured suture from above the arteriot-
omy rather than having a platform where needles were actually
positioned in the artery and delivered suture to the surface. We
believe that the Closer provided a patient safety feature and greater
reliability, which may not have been reflected in the meta-analysis,
which included 15 Perclose-related studies on the older TechStar
and ProStar product lines reported by Nikolsky. A more recent
patient set was examined by Tavris et al. (2), where analysis of the
large ACC-NCDR database of 166,680 patients saw a reduction
in vascular complications and death in patients who had the
Angio-Seal and Perclose vascular closure devices used when
compared to manual compression or compression devices. This
finding was assessed from patient data collected between 2001 and
2002.
Similarly, a meta-analysis may not reflect a change in practice
style or technique, which might be better detected in a randomized
clinical trial or database survey. Of the 15 Perclose studies
examined, only 4 were with 6- to 7-F sheaths; the others were
actually larger sheath sizes, which is uncommon in practice over
the past five to six years. Suture-based devices in particular have
been commonly used in larger-diameter puncture sites. Closure
devices have reduced their size as practice patterns have moved
toward a smaller dimension, and this shift may be reflected in
outcomes seen with the newer devices as well as with manual
compression with or without a compression-assist device.
Despite the criticisms mentioned above, the Nikolsky et al. (1)
study is an important signal for our field. Although no study is
perfect, reports such as those by Nikolsky et al. (1) and Tavris et al.
(2) have shown that the predominant technologies on the market
are equivalent and potentially superior to manual compression in
providing patient comfort and safety. Higher-risk clinical scenarios
have to be considered, especially in the female patient (3); however,
the time may be ripe for more study and a head-to-head random-
ized clinical trial.
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REPLY
We reviewed carefully the comments of Dr. Chou regarding our
recent study (1). A meta-analysis always has several limitations,
which we listed in the respective section of our report and which
Dr. Chou outlines in his letter. The main issue of the multiple
small size, uncontrolled, and often unpublished (as complete
papers) studies in the area of vascular closure devices can be
attributed to the existence of multiple generations of all devices
and to the funding variability (or difficulty to obtain adequate
research grants from industry). Similarly, a database analysis (2) is
also limited by the uncontrolled, rather random (and certainly
nonconsecutive) data entry and the absence of event review and
adjudication by an independent committee. Moreover, Dr. Chou’s
claim that more recent-generation devices are included is a very
reasonable presumption but is not explicitly documented. These
limitations of the way the queried database is set up have nothing
to do with the elegant way the data were handled by Tavris et al.
(2) but still deserve to be outlined.
Therefore, we do not believe that adequate reasons exist to
declare one type of analysis “more meaningful” than the other, but
we certainly endorse the expressed interest by a major industry
stakeholder for a large, randomized study. This is what is needed
the most in this subject.
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Heart Failure Training: Care for
Older Adults With Chronic Heart Failure
Studies by Adamson et al. (1) and Konstam (2) eloquently
highlight the need for heart failure (HF) specialists. As drug and
device therapies for HF are rapidly evolving, it is difficult even for
cardiologists to stay abreast of. Internists, family physicians, and
geriatricians, who treat the vast majority of HF patients, often
underutilize angiotensin-converting enzyme (ACE) inhibitors or
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